ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth

US-Based Firm Says Motegrity ‘Genericization Levels Significantly Higher’ Than Reported

ANI Pharmaceuticals says it has delivered an “exceptionally strong first quarter,” with total sales reaching over $197m, amid plans to kick off a Phase IV clinical trial for Cortrophin Gel for acute gouty arthritis later this year.

(Shutterstock)

More from Earnings

More from Products